The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM

More documents

Recommendations

Info

Normal Gram-negative
Resistance Mechanisms Inactivating Enzymes Alterations in Target Altered Permeability Outermembrane Porins Active Efflux
Page 1: The Evolving Threat of ESBL, AmpC,
Page 6 and 7: ß-lactamases O CH 2 C NH O N S CH
Page 8 and 9: Old Plasmid-Encoded ß-lactamases T
Page 10 and 11: 3 rd Generation Cephalosporins Cefo
Page 12 and 13: Evolution of ESBLs TEM-3, 4 ......
Page 14 and 15: ESBL-producing Organisms Most Commo
Page 16 and 17: CLSI 2010 (M100-S20) • If laborat
Page 18 and 19: 2010 Breakpoints: Are they sufficie
Page 20: Inoculum Effect: In Vitro Artifact?
Page 23 and 24: -lactams Still Active Carbapenems C
Page 25 and 26: AmpC-mediated Resistance Resistant
Page 27 and 28: Plasmid-mediated AmpCs • Klebsiel
Page 29 and 30: Clinical Significance of AmpC for K
Page 31 and 32: Klebsiella pneumoniae 225 Resistant
Page 34 and 35: Carbapenemases Class A (KPC, GES, S
Page 36 and 37: Miami KPC Outbreak • Admission fi
Page 38 and 39: Which MIC do we use? Carbapenem MIC
Page 41: Thanks for your attention!

The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?